News

Flagship Biosciences ActionAnalysis Solutions Accelerate Drug Development

Back to News

Ready-to-use and custom image analysis meets current and future development needs

Westminster, CO, February 12, 2018 – Flagship Biosciences is adding to its menu of ready-to-use image solutions with the introduction of ActionAnalysisTM. As the most experienced, integrated clinical laboratory, Flagship’s ActionAnalysis solutions help drug developers rapidly evaluate existing targets to define a biomarker-driven path to success.

ActionAnalysis accelerates and simplifies tissue image analysis through trend analysis, tissue wide expression and relative rank ordering, with no upfront algorithm development.

ActionAnalysis quickly generates hypotheses to help drug developers focus their biomarker strategy, reduce the risk of failure and accelerate drug development,” says Trevor Johnson, Flagship General Manager and COO. “We offer the experience and expertise to facilitate critical decision points at every stage of development, from generating hypotheses about mechanism of action, to patient selection and companion diagnostics.”

As the only fully integrated, full-service image analysis and CLIA-certified lab service in the U.S., Flagship combines the expertise of pathologists, scientists, histologists and image analysts to generate and interpret contextual tissue data and answer the most challenging pathology questions.

Visit Flagship Biosciences at the Molecular Medicine Tri-Conference, February 12-14, 2018, booth #119, to learn more about ActionAnalysis and Flagship’s Computational Tissue Analysis (cTA) solutions for precision medicine.

Media Contact:
Amy Shannon
VP, Sales & Marketing
ashannon@flagshipbio.com
303.608.9008

Share this Post: